IONS logo

IONS
Ionis Pharmaceuticals Inc

6,665
Mkt Cap
$12.44B
Volume
1.82M
52W High
$86.74
52W Low
$31.66
PE Ratio
-35.81
IONS Fundamentals
Price
$75.28
Prev Close
$74.76
Open
$74.86
50D MA
$75.31
Beta
0.72
Avg. Volume
1.77M
EPS (Annual)
-$2.38
P/B
25.41
Rev/Employee
$673,117.69
$12,595.28
Loading...
Loading...
News
all
press releases
Kornitzer Capital Management Inc. KS Buys Shares of 29,105 Ionis Pharmaceuticals, Inc. $IONS
Kornitzer Capital Management Inc. KS bought a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the fourth quarter, according to its most recent filing with the Securities...
MarketBeat·4h ago
News Placeholder
More News
News Placeholder
Ionis Pharmaceuticals (NASDAQ:IONS) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded shares of Ionis Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·1d ago
News Placeholder
Vanguard Group Inc. Sells 41,271 Shares of Ionis Pharmaceuticals, Inc. $IONS
Vanguard Group Inc. decreased its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 0.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,440,459 shares of the company's...
MarketBeat·2d ago
News Placeholder
Ionis to present at upcoming investor conferences
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Bank of America Securities 2026 Health Care...
Business Wire·2d ago
News Placeholder
Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says
Royal Bank Of Canada upped their target price on shares of Ionis Pharmaceuticals from $95.00 to $100.00 and gave the company an "outperform" rating in a report on Thursday...
MarketBeat·3d ago
News Placeholder
IONS Q1 Earnings & Sales Beat, Stock Rises on Raised '26 View
Ionis tops Q1 estimates and lifts 2026 outlook, drives shares higher as strong drug sales and milestone revenues fuel growth.
Zacks·3d ago
News Placeholder
Ionis Pharmaceuticals Q1 Earnings Call Highlights
Ionis Pharmaceuticals (NASDAQ:IONS) reported sharply higher first-quarter 2026 revenue and raised its full-year outlook, citing accelerating demand for its two commercial products and milestone-driven partner revenue. Management also outlined upcoming regulatory milestones and launch preparations fo...
MarketBeat·4d ago
News Placeholder
Ionis Pharmaceuticals (NASDAQ:IONS) Issues Quarterly Earnings Results
Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.56) earnings per share for the quarter, topping analysts' consensus...
MarketBeat·4d ago
News Placeholder
GSK Q1 Earnings Beat Estimates, Specialty Medicines Drive Sales Growth
GSK Q1 earnings and revenues beat estimates as Specialty Medicines lifted sales, with HIV, oncology and respiratory growth. The guidance for 2026 remains unchanged.
Zacks·4d ago
News Placeholder
Compared to Estimates, Ionis Pharmaceuticals (IONS) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·4d ago
<
1
2
...
>

Latest IONS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.